黄芪注射液对慢性阻塞性肺疾病患者肺功能的影响

Effect of Astragalus Injection on lung function observed in patients with COPD

目的:观察黄芪注射液治疗慢性阻塞性肺疾病的临床效果。方法:选取我科室2014年2月至2015年8月收治疗的确诊为慢性阻塞性肺疾病的患者共90例,按随机数字表发分为观察组和对照组各45例,观察组患者在常规治疗的基础上给予黄芪注射液治疗,对照组给予基础治疗,随访并记录两组患者相关指标变化情况。结果:治疗1月后,观察组血清气道重塑指标碱性成纤维细胞生长因子、神经生长因子、基质金属蛋白酶抑制剂-1值分别为(94.0±16.3ug/L、100.4±21.0ng/L、37.0±4.3ng/ml),均明显优于对照组(129.8±17.8ug/L、144.7±22.8ng/L、52.6±5.1ng/ml)。治疗1月后,观察组痰液炎性指标IL-8、IL-18、TNF-α分别为(10.2±1.6pg/ml、31.0±6.9pg/ml、14.3±1.4ng/L),均明显优于对照组(17.5±1.7pg/ml、87.1±10.6pg/ml、21.7±1.9ng/L)。治疗1月后,观察组血气指标PaO_2、PaCO_2、pH值分别为(89.3±6.7mm Hg、36.3±5.3mm Hg、7.4±0.1),均明显优于对照组(76.5±5.4mm Hg、42.6±6.5mm Hg、7.4±0.9)。4治疗1月后,观察组血清炎性指标IL-8、IL-18、TNF-α分别为(7.5±1.3pg/ml、20.4±5.3pg/ml、4.1±0.6ng/L),均明显优于对照组(15.0±1.6pg/ml、62.0±9.3pg/ml、9.5±1.4ng/L)。5治疗1月后,观察组的用力肺活量(FVC)、一秒用力呼气容积(FEV1)和FEV1/FVC为别为(3.1±0.2L、2.8±0.3L、72.2±1.6%),均明显优于对照组(2.8±0.2L、2.0±0.2L、69.4±1.4%)。结论:黄芪注射液治疗慢性阻塞性肺疾病效果良好,优于单独运用基础治疗。

Objective： To observe the clinical effects of Astragalus Injection treatment of chronic obstructive pulmonary disease. Methods： 90 pa- tients from February 2014 to August 2015, were randomly divided into two groups and made all 45 cases in the control group, patients in the observation group Astragalus injection treatment given on the basis of conventional therapy, the control group were given basic treatment, pa- tients were followed up and record changes related indicators. Results： （1） 1 month after treatment , The serum levels of airway remodeling index of basic fibroblast growth factor, nerve growth factor, matrix metalloproteinase inhibitor-1 values were （94.0 ±16.3ug/L, 100.4 ±21. Ong/L, 37.0 ±4.3ng/ml）, than the control group （ 129.8±17.8ug/L, 144.7± 22.8ng/L, 52.6± 5. 1 ng/ml）, and the differences were statistically significant （ P 〈 0.05 ）. （2） 1 month after treatment, the observation group sputum inflammatory markers IL-8, IL-18, TNF-α, respectively （ 10.2 ± 1.6pg/ml, 31.0 ± 6.9pg/ml, 14.3 ± 1.4ng/L） , are excellent in the control group （ 17.5 ± 1.7pg/ml, 87.1 ± 10.6pg/ ml, 21.7 ± 1.9ng/L）, and the differences were statistically significant （ p 〈 0.05 ）. （3） 1 month after treatment, the observation group blood gas PaO2 , PaCO2 , PH value, respectively （89.3 ± 6.7mmHg, 36.3 ± 5.3mmHg, 7.4 ± 0.1 ）, than the control group （76.5 ± 5.4mmHg, 42.6 ± 6.5mmHg, 7.4 ± 0.9） , and the differences were statistically significant （ p 〈 0.05 ）. （4） After treatment in January, observed in ser- um inflammatory markers IL-8, IL-18, TNF-α, respectively （ 7.5±1.3pg/ml, 20.4 ± 5.3pg/ml, 4. 1 ± 0. 6ng/L）, are excellent in the control group （ 15.0 ± 1.6pg/ml, 62.0 ± 9.3pg/ml, 9.5 ± 1.4ng/L） , and the differences were statistically significant （ p 〈 0.05 ）. （5） 1 month after treatment, observation group forced vital capacity （FVC） , forced expiratory volume in one second （FEV1） and FEVI/FVC is not as （ 3.1 ± 0.2L,2.8 ± 0.3L,72.2 ± 1.6% ）, are better than the control group （ 2.8 ± 0.2L,2.0 ± 0.2L,69.4 ± 1.4% ）, and the differ- ence was significant （ p 〈 0.05 ）. Conclusion： Astragalus Injection treatment of chronic obstructive pulmonary disease effect is good, better than the use of basic treatment alone is worthy of further research and aoolieation.